Market Overview

Vetr Upgrades Celgene After Drug Trial Stalls

Related CELG
5 Biotech Companies To Keep On Your M&A Watchlist For 2019
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You? (Seeking Alpha)

The Vetr crowd on Monday upgraded its rating on Celgene Corporation (NASDAQ: CELG) from 3 stars (Buy) issued 16 days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was unanimously positive, with 100 percent of Vetr user ratings bullish.

Vetr's upgrade comes on the heels of biotech's announcement that it would be discontinuing trials of its crohn's disease drug treatment. Following the news, analysts with Baird and Piper Jaffray downgraded the stock while a slew of others, including analysts with UBS and Barclays, lowered their outlook on the company.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Celgene is up at $144.39, which is above the average analyst price target of $140.50. Less than 2 percent of Vetr users are holding CELG in their watch-lists.

Latest Ratings for CELG

Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General


Related Articles (CELG)

View Comments and Join the Discussion!

Latest Ratings

MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Earnings Scheduled For October 24, 2017

Benzinga's Option Alert Recap From October 23